EGFR and neoplasm: Indeed, the analysis of public available data leads to the suggestion that, irrespective of oncogenic driver, an increased expression of USP28 significantly shortens survival for tumours driven by mutations in the oncogenes EGFR (∆574 days), PIK3CA (∆177 days) or BRAF (∆922 days), while in tumours driven by mutations in genes of the RAS family, USP28 had very little effect on patient survival (∆58 days; Fig. 7B and Fig. S8D).